Market Overview

UPDATE: Credit Suisse Initiates Immunogen at Neutral on Valuation

Share:
Related IMGN
Mid-Afternoon Market Update: Dow Gains 90 Points; Micronet Enertec Technologies Shares Drop
9 Notable Biotechs Presenting At This Year's ASH Meeting

Credit Suisse initiated coverage on Immunogen (NASDAQ: IMGN) with a Neutral rating and a $12 price target.

Credit Suisse noted, "We like IMGN for its expected steady cash flow from T-DM1 royalties, its antibody-drug conjugation (ADC) technology, and potential upside from a deep pipeline. However, upside to valuation requires additional drivers for which visibility is currently low."

Immunogen closed at $11.65 on Monday.

Latest Ratings for IMGN

DateFirmActionFromTo
Aug 2017Canaccord GenuityMaintainsBuy
Jul 2017Morgan StanleyMaintainsUnderweight
Jul 2017RBC CapitalUpgradesSector PerformOutperform

View More Analyst Ratings for IMGN
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (IMGN)

View Comments and Join the Discussion!

Partner Center